Data in longitudinal randomised controlled trials in cancer pain: is there any loss of the information available in the data? Results of a systematic literature review and guideline for reporting

Sauzet O, Kleine M, Williams JE (2016)
BMC Cancer 16: 771.

Download
OA 599.35 KB
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Volltext vorhanden für diesen Nachweis
Autor
Abstract / Bemerkung
Background Given the prevalence of untreated pain among cancer patients, there have been calls for more and better research in the domain. Increasingly, calls for less waste and more optimal use of trial data collected are being made. Waste of data includes non-optimal statistical analysis and non-presentation of interpretable effect size as a measure of effectiveness of an intervention which also enable comparisons across studies. Methods We reviewed the recent literature on randomised trials on longitudinal cancer pain to identify sources of loss of data information by collecting material on the nature of outcomes collected, analysed, the method of analysis and what was presented as a result of the trial. Illustrated with real data, we propose some guidelines on how to adequately analyse longitudinal data and report the results using mixed models. Results We identified some major source of data information loss, one of which is the transformation of a continuous pain outcome. Not adjusting for the collected outcome baseline value is moreover a source of bias. Multiple testing by analysing the data cross-sectionnally at each time-point leads to loss of information and power. Finally, effect sizes reflecting the effectiveness of the intervention were never reported. Conclusions We identified several sources of information loss in the way longitudinal trials on pain were analysed and reported. However these problems could be easily solved by using regression methods like mixed models and presenting regression parameters to provide a concrete quantitative effect of the intervention.
Erscheinungsjahr
Zeitschriftentitel
BMC Cancer
Band
16
Art.-Nr.
771
eISSN
Finanzierungs-Informationen
Article Processing Charge funded by the Deutsche Forschungsgemeinschaft and the Open Access Publication Fund of Bielefeld University.
PUB-ID

Zitieren

Sauzet O, Kleine M, Williams JE. Data in longitudinal randomised controlled trials in cancer pain: is there any loss of the information available in the data? Results of a systematic literature review and guideline for reporting. BMC Cancer. 2016;16: 771.
Sauzet, O., Kleine, M., & Williams, J. E. (2016). Data in longitudinal randomised controlled trials in cancer pain: is there any loss of the information available in the data? Results of a systematic literature review and guideline for reporting. BMC Cancer, 16, 771. doi:10.1186/s12885-016-2818-8
Sauzet, O., Kleine, M., and Williams, J. E. (2016). Data in longitudinal randomised controlled trials in cancer pain: is there any loss of the information available in the data? Results of a systematic literature review and guideline for reporting. BMC Cancer 16:771.
Sauzet, O., Kleine, M., & Williams, J.E., 2016. Data in longitudinal randomised controlled trials in cancer pain: is there any loss of the information available in the data? Results of a systematic literature review and guideline for reporting. BMC Cancer, 16: 771.
O. Sauzet, M. Kleine, and J.E. Williams, “Data in longitudinal randomised controlled trials in cancer pain: is there any loss of the information available in the data? Results of a systematic literature review and guideline for reporting”, BMC Cancer, vol. 16, 2016, : 771.
Sauzet, O., Kleine, M., Williams, J.E.: Data in longitudinal randomised controlled trials in cancer pain: is there any loss of the information available in the data? Results of a systematic literature review and guideline for reporting. BMC Cancer. 16, : 771 (2016).
Sauzet, Odile, Kleine, Maren, and Williams, John E. “Data in longitudinal randomised controlled trials in cancer pain: is there any loss of the information available in the data? Results of a systematic literature review and guideline for reporting”. BMC Cancer 16 (2016): 771.
Alle Dateien verfügbar unter der/den folgenden Lizenz(en):
Copyright Statement:
This Item is protected by copyright and/or related rights. [...]
Volltext(e)
Access Level
OA Open Access
Zuletzt Hochgeladen
2017-09-19T07:23:06Z

1 Zitation in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Pain prevalence in cancer patients: status quo or opportunities for improvement?
Haumann J, Joosten EBA, Everdingen MHJVDB., Curr Opin Support Palliat Care 11(2), 2017
PMID: 28306569

18 References

Daten bereitgestellt von Europe PubMed Central.

Management of cancer pain: ESMO Clinical Practice Guidelines.
Jost L, Roila F; ESMO Guidelines Working Group., Ann. Oncol. 21 Suppl 5(), 2010
PMID: 20555093
Prevalence of undertreatment in cancer pain. A review of published literature.
Deandrea S, Montanari M, Moja L, Apolone G., Ann. Oncol. 19(12), 2008
PMID: 18632721
Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer.
Fisch MJ, Lee JW, Weiss M, Wagner LI, Chang VT, Cella D, Manola JB, Minasian LM, McCaskill-Stevens W, Mendoza TR, Cleeland CS., J. Clin. Oncol. 30(16), 2012
PMID: 22508819
Prevalence of pain in patients with cancer: a systematic review of the past 40 years.
van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J., Ann. Oncol. 18(9), 2007
PMID: 17355955

AUTHOR UNKNOWN, 0
American pain society recommendations for improving the quality of acute and cancer pain management: American Pain Society Quality of Care Task Force.
Gordon DB, Dahl JL, Miaskowski C, McCarberg B, Todd KH, Paice JA, Lipman AG, Bookbinder M, Sanders SH, Turk DC, Carr DB., Arch. Intern. Med. 165(14), 2005
PMID: 16043674

CI, Ann Oncol Off J Eur Soc Med Oncology/ESMO 23(Suppl 7), 2012

AUTHOR UNKNOWN, 0
Clinical trials: what a waste.
Ioannidis JP., BMJ 349(), 2014
PMID: 25499097
Assessment of pain.
Breivik H, Borchgrevink PC, Allen SM, Rosseland LA, Romundstad L, Hals EK, Kvarstein G, Stubhaug A., Br J Anaesth 101(1), 2008
PMID: 18487245
Core outcome measures for chronic pain clinical trials: IMMPACT recommendations.
Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J; IMMPACT., Pain 113(1-2), 2005
PMID: 15621359
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group, Altman D, Antes G, Atkins D, Barbour V, Barrowman N, Berlin JA, Clark J, Clarke M, Cook D, D'Amico R, Deeks JJ, Devereaux PJ, Dickersin K, Egger M, Ernst E, Gotzsche PC, Grimshaw J, Guyatt G, Higgins J, Ioannidis JP, Kleijnen J, Lang T, Liberati A, Magrini N, McNamee D, Moja L, Moher D, Mulrow C, Napoli M, Oxman A, Pham B, Rennie D, Sampson M, Schulz KF, Shekelle PG, Tetzlaff J, Tovey D, Tugwell P., Ann. Intern. Med. 151(4), 2009
PMID: 19622511
Routine screening for pain combined with a pain treatment protocol in head and neck cancer: a randomised controlled trial.
Williams JE, Peacock J, Gubbay AN, Kuo PY, Ellard R, Gupta R, Riley J, Sauzet O, Raftery J, Yao G, Ross J., Br J Anaesth 115(4), 2015
PMID: 26385671
The cost of dichotomising continuous variables.
Altman DG, Royston P., BMJ 332(7549), 2006
PMID: 16675816

AUTHOR UNKNOWN, 0

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 27716116
PubMed | Europe PMC

Suchen in

Google Scholar